SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities
Human coronaviruses, especially SARS-CoV-2, are emerging pandemic infectious diseases with high morbidity and mortality in certain group of patients. In general, SARS-CoV-2 causes symptoms ranging from the common cold to severe conditions accompanied by lung injury, acute respiratory distress syndro...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464614/ https://www.ncbi.nlm.nih.gov/pubmed/32764454 http://dx.doi.org/10.3390/cancers12082186 |
_version_ | 1783577403901083648 |
---|---|
author | Gupta, Ishita Rizeq, Balsam Elkord, Eyad Vranic, Semir Al Moustafa, Ala-Eddin |
author_facet | Gupta, Ishita Rizeq, Balsam Elkord, Eyad Vranic, Semir Al Moustafa, Ala-Eddin |
author_sort | Gupta, Ishita |
collection | PubMed |
description | Human coronaviruses, especially SARS-CoV-2, are emerging pandemic infectious diseases with high morbidity and mortality in certain group of patients. In general, SARS-CoV-2 causes symptoms ranging from the common cold to severe conditions accompanied by lung injury, acute respiratory distress syndrome in addition to other organs’ destruction. The main impact upon SARS-CoV-2 infection is damage to alveolar and acute respiratory failure. Thus, lung cancer patients are identified as a particularly high-risk group for SARS-CoV-2 infection and its complications. On the other hand, it has been reported that SARS-CoV-2 spike (S) protein binds to angiotensin-converting enzyme 2 (ACE-2), that promotes cellular entry of this virus in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2). Today, there are no vaccines and/or effective drugs against the SARS-CoV-2 coronavirus. Thus, manipulation of key entry genes of this virus especially in lung cancer patients could be one of the best approaches to manage SARS-CoV-2 infection in this group of patients. We herein provide a comprehensive and up-to-date overview of the role of ACE-2 and TMPRSS2 genes, as key entry elements as well as therapeutic targets for SARS-CoV-2 infection, which can help to better understand the applications and capacities of various remedial approaches for infected individuals, especially those with lung cancer. |
format | Online Article Text |
id | pubmed-7464614 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74646142020-09-04 SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities Gupta, Ishita Rizeq, Balsam Elkord, Eyad Vranic, Semir Al Moustafa, Ala-Eddin Cancers (Basel) Review Human coronaviruses, especially SARS-CoV-2, are emerging pandemic infectious diseases with high morbidity and mortality in certain group of patients. In general, SARS-CoV-2 causes symptoms ranging from the common cold to severe conditions accompanied by lung injury, acute respiratory distress syndrome in addition to other organs’ destruction. The main impact upon SARS-CoV-2 infection is damage to alveolar and acute respiratory failure. Thus, lung cancer patients are identified as a particularly high-risk group for SARS-CoV-2 infection and its complications. On the other hand, it has been reported that SARS-CoV-2 spike (S) protein binds to angiotensin-converting enzyme 2 (ACE-2), that promotes cellular entry of this virus in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2). Today, there are no vaccines and/or effective drugs against the SARS-CoV-2 coronavirus. Thus, manipulation of key entry genes of this virus especially in lung cancer patients could be one of the best approaches to manage SARS-CoV-2 infection in this group of patients. We herein provide a comprehensive and up-to-date overview of the role of ACE-2 and TMPRSS2 genes, as key entry elements as well as therapeutic targets for SARS-CoV-2 infection, which can help to better understand the applications and capacities of various remedial approaches for infected individuals, especially those with lung cancer. MDPI 2020-08-05 /pmc/articles/PMC7464614/ /pubmed/32764454 http://dx.doi.org/10.3390/cancers12082186 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Gupta, Ishita Rizeq, Balsam Elkord, Eyad Vranic, Semir Al Moustafa, Ala-Eddin SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities |
title | SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities |
title_full | SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities |
title_fullStr | SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities |
title_full_unstemmed | SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities |
title_short | SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities |
title_sort | sars-cov-2 infection and lung cancer: potential therapeutic modalities |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464614/ https://www.ncbi.nlm.nih.gov/pubmed/32764454 http://dx.doi.org/10.3390/cancers12082186 |
work_keys_str_mv | AT guptaishita sarscov2infectionandlungcancerpotentialtherapeuticmodalities AT rizeqbalsam sarscov2infectionandlungcancerpotentialtherapeuticmodalities AT elkordeyad sarscov2infectionandlungcancerpotentialtherapeuticmodalities AT vranicsemir sarscov2infectionandlungcancerpotentialtherapeuticmodalities AT almoustafaalaeddin sarscov2infectionandlungcancerpotentialtherapeuticmodalities |